Guest guest Posted April 6, 2001 Report Share Posted April 6, 2001 In a message dated 4/6/01 9:12:49 AM Central Daylight Time, Ssadlermas@... writes: << << These are the ingredients in the TF Plus, right? My understanding is that this isn't recommended for anyone w/autoimmune disorders - those folks are suggested to use just the Transfer Factor (vs the TF Plus). >> This is true but lyme is not an auto-immune disorder. >> OK, well, what if you are like me and Lyme has caused a dysfunctional immune system? I technically also have Chronic Fatigue Immune Dysfunction Syndrome also as I meet all the CDC criteria, have low Natural Killer Cells, out of balance CD4-CD8 ratios, etc. Would it be detrimental to take it? Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 6, 2001 Report Share Posted April 6, 2001 In a message dated 4/6/01 11:46:44 AM, golfdawg@... writes: << OK, well, what if you are like me and Lyme has caused a dysfunctional immune system? I technically also have Chronic Fatigue Immune Dysfunction Syndrome also as I meet all the CDC criteria, have low Natural Killer Cells, out of balance CD4-CD8 ratios, etc. Would it be detrimental to take it? >> I am not a dr. and I would advise that you call 4Life themselves and ask. Technically from my resources lyme and chronic fatigue are basically one in the same. We all have low NK cells, we are 'out of balance'. It is up to each individual to make that judgment. Sue in nj Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 6, 2001 Report Share Posted April 6, 2001 In a message dated 4/6/01 11:46:44 AM, golfdawg@... writes: << OK, well, what if you are like me and Lyme has caused a dysfunctional immune system? I technically also have Chronic Fatigue Immune Dysfunction Syndrome also as I meet all the CDC criteria, have low Natural Killer Cells, out of balance CD4-CD8 ratios, etc. Would it be detrimental to take it? >> I am not a dr. and I would advise that you call 4Life themselves and ask. Technically from my resources lyme and chronic fatigue are basically one in the same. We all have low NK cells, we are 'out of balance'. It is up to each individual to make that judgment. Sue in nj Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 6, 2001 Report Share Posted April 6, 2001 You should take the regular Transfer Factor not the plus as the plus increases natural killer cells which is what affects the body in autoimmune stages. . FrancineRN NJ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 14, 2001 Report Share Posted April 14, 2001 It was originally thought that transfer factor could only be transferred successfully through the blood, and thus was administered either by injection or transfusion. The process of extracting the transfer factors from blood was very costly and time consuming. Human blood sources included live donors, outdated blood from blood banks, but using human blood sources includes all the hazards associated with blood transfusions such as HIV and Hepatitis. In additio, neither freshly drawn nor outdated blood from blood banks was an adequate source for commerical transfer factor. Therefore, large doses would be given a monthly basis. These studies were done in the 70's and 80's. Now many believe that the colostrum in diary milk is the best source of transfer factor. Harvesting the excess colostrum and isolating its transfer factor supply provides an abundant and beneficial source of transfer factor for human consumption. Later more recent studies have shown that transfer factor was equally as effective when taken orally. This observation is consistent with studies on oral absorption of other peptides of similar size. Hope this answers your question? Jana Transfer Factor > Hi, > Here is some more information on Transfer Factor. > In one study below Transfer Factor was given once a month, yet people using it for > themselves usually take Transfer Factor daily. Why would they give it only once a > month in the clinical trial? > > moonbeam > > 1: Gan No Rinsho 1983 Oct;29(12):1409-16 > > Transfer factor immunochemotherapy for primary lung cancer--evaluation of > histologic types. > > [Article in Japanese] > > Fujisawa T, Yamaguchi Y > > The clinical effect of leucocyte dialysate, including Transfer Factor (TF), on > different histologic types of primary resected lung cancer was studied. Eligible > cases for evaluation were randomly chosen; the TF group and control group consisted > of 75 and 74 patients, respectively. The TF group included 40 adenocarcinomas, 29 > epidermoid carcinomas and 6 other histologic types of carcinoma. The control group > included 42 adenocarcinomas, 25 epidermoid carcinomas and 7 other histologic types > of carcinoma. The postoperative follow-up term was 2 to 55 months in both groups. > Survival in the TF group of patients with adenocarcinoma of stages I + II or > curative resection was significantly better than in the control group (p less than > 0.005, -Mantel test). There was no significant intergroup difference in patients > with stages III + IV, relative curative or noncurative resection. Survival in > the TF group of patients with epidermoid carcinoma of stages I + II or III + IV > was about 20% better than in the control. Survival in the TF group of patients > undergoing relative curative resection was significantly better than in > the control (p less than 0.005, -Mantel test). > There was a significant difference between patients with stages I + II, but not > between patients with stages III + IV. The frequency of recurrence of regional > or intrapulmonary distant metastasis was lower in the TF group. It is suggested > that TF suppresses postoperative recurrence and that it may be beneficial as > postoperative adjuvant immunochemotherapy in primary resected lung cancer > patients, especially those with relatively early stage cancer. > > PMID: 6315989 > -------------------------------------------------------------- > > 1: Biotherapy 1996;9(1-3):117-21 > > Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. > > Pilotti V, Mastrorilli M, Pizza G, De Vinci C, Busutti L, Palareti A, Gozzetti > G, Cavallari A > > Istituto di Clinica Chirurgica II, S. Orsola-Malpighi, Bologna, Italy. > > The rationale for using transfer factor (TF) in lung cancer patients is that the > possibility of improving their cell-mediated immunity to tumour associated > antigens (TAA) may improve their survival. From Jan 1984 to Jan 1995, 99 > non-small cell lung cancer (NSCLC) resected patients were monthly treated with > TF, extracted from the lymphocytes of blood bank donors. In the same period, 257 > NSCLC resected patients were considered as non-treated controls. The survival > rates of the TF treated group appear significantly improved both for patients in > stages 3a and 3b, and patients with histological subtype " large cell carcinoma " > (P < 0.02). Survival of TF treated patients is also significantly higher (P < > 0.02) for patients with lymph node involvement (N2 disease). The results of this > study suggest that the administration of TF to NSCLC resected patients may > improve survival. > > Publication Types: > Clinical trial > Controlled clinical trial > > PMID: 8993769 > ------------------------------------------------------- > > 1: Cancer Detect Prev Suppl 1987;1:373-6 > > Transfer factor for adjuvant immunotherapy in cervical cancer. > > Wagner G, Knapp W, Gitsch E, Selander S > > 1st Department of Obstetrics and Gynecology, University of Vienna, Austria. > > In a prospective randomized double-blind study of 60 patients with invasive > cervical cancer, 32 were treated with transfer factor (TF) derived from > leukocytes of the patients' husbands, and 28 were treated with placebo. Within > the first 2 years after radical hysterectomy, five out of 32 TF-treated patients > and 11 out of 28 placebo-treated patients developed recurrence of malignancy. > This difference is significant (chi 2 = 3.9915; P less than 0.05). > > PMID: 3319147 > ----------------------------------------------------------------- > > 1: Biotherapy 1996;9(1-3):123-32 > > A preliminary report on the use of transfer factor for treating stage D3 > hormone-unresponsive metastatic prostate cancer. > > Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, > Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P, Fornarola > V, Viza D > > Reports have suggested the existence of > humoral and cell-mediated immunity (CMI) against prostate cancer > tumour-associated antigens (TAA). > Fifty patients entered this study and received one intramuscular injection of 2-5 > units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that > complete remission was achieved in 2 patients, partial remission in 6, and no > progression of metastatic disease in 14. The median survival was 126 weeks, > higher than the survival rates reported in the literature for patients of the > same stage. > > Publication Types: > Clinical trial > > PMID: 8993770 > > > > > > > > > > > > > > > > > > Get HUGE info at http://www.cures for cancer.ws, and post your own links there. Unsubscribe by sending email to cures for cancer-unsubscribeegroups or by visiting http://www.bobhurt.com/subunsub.mv > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 7, 2001 Report Share Posted June 7, 2001 Â Â Â hi feige2see, <<< Anyone who has been on transfer factor seeing any results?I think I read one message in the last three months >>> i used to post periodic updates. haven't posted one in quite a while. i still have a 14yr old (15 in a week) on the full dose of the 560 (3 capsules a day). she's been on it for about 16 months now. she DOES do better, and i have no plans to take her off. she had a bad " crash " over the winter (thanks to the school - long story, but it's been resolved - think they have a bit of a " clue " now). she starts 9th grade in the fall. she'll just do academics - so she'll be prepared to pass a GED some day. she'll be taking two classes - which they call " blocks " , an hour and a half each, a half day. it'll be about 11:30am to 2:30pm. she'll then have a homebound teacher to help her with those two classes. it may turn out to be a bit too much, and she may not do great grade-wise, but hopefully, she'll get enough out of it to pass the GED... really have not idea at this point. she seems pretty " happy " , " normal " , well adjusted at this point. she WANTS to be at school. and of course wants to do a whole lot more than she can, and attempts it ... ~~~~~~~~~~~~~~~~~~~~~~~~~ " Would they have found nothing, unless nothing was what they wanted to find? " - Agent Dales, X-Files @}{~{<<~~~~~~~~~~~~~~~~~~~~ @}{~{<<~~~~~~~~~~~~~~~~~~~~ debbie s. - dlsherman@... Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 8, 2001 Report Share Posted June 8, 2001 All I have noticed is that it now makes me somewhat less sick when I take it (once a week, TID) > Anyone who has been on transfer factor seeing any results?I think I > read one message in the last three months,where one person stated it > helped.I started three months ago,several people in the group started > the same time with heparin and isoprinosine,would like to hear how > you are doing. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 9, 2001 Report Share Posted June 9, 2001 I have put my blab about this on www.austarmetro.com.au/~julian/tf.html n At 23:14 08/06/01, you wrote: > > Anyone who has been on transfer factor seeing any results?I think I > > read one message in the last three months,where one person stated it > > helped.I started three months ago,several people in the group started > > the same time with heparin and isoprinosine,would like to hear how > > you are doing. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 9, 2001 Report Share Posted June 9, 2001 Thank you for your post on TF. I didn't have any luck with the colostrum doses in Biomune OSF - was hoping plain old TF would be a better hammer (and more cost effective). Question: do dairy-allergic people have a potential problem here? I recently tried Immunocal and don't know whether my reaction was allergic or die-off, and was considering NAET treatment. - N. in CA n wrote: > I have put my blab about this on www.austarmetro.com.au/~julian/tf.html > > n > > At 23:14 08/06/01, you wrote: > > > Anyone who has been on transfer factor seeing any results?I think I > > > read one message in the last three months,where one person stated it > > > helped.I started three months ago,several people in the group started > > > the same time with heparin and isoprinosine,would like to hear how > > > you are doing. > > This list is intended for patients to share personal experiences with each other, not to give medical advice. If you are interested in any treatment discussed here, please consult your doctor. > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 9, 2001 Report Share Posted June 9, 2001 I am dairy sensitive and can't use immunocal, but TF is no problem. TF itself contains nothing that you are likely to be allergic to (no big proteins or lactose), but sometimes it is packaged with small amounts of milk product like whey. Even then I've not noticed a problem. n At 17:19 09/06/01, you wrote: >was hoping plain old TF would be a better hammer (and more cost >effective). Question: do >dairy-allergic people have a potential problem here? Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 28, 2001 Report Share Posted July 28, 2001 Hi Luke and n, Have been reading your post about Transfer Factor C or Chisolm #2 with great interest. Have dug out a long question and answer session of Dr. Fundenberg back in 93'. He said the best Transfer Factor was from one person that had lived with the ill person for at least 6 mos to get a good transfer factor from their blood. He was helping too many people I guess and they finally but him out of business. I had contacted him back then and he had sent me papers to fill out but couldn't talk my husband into going to SC. My question is and can't seem to find it in the web sites that I have looked at is Transfer Factor #2 or TF C made from human blood? From what I have gathered this is the best provided it is safe. I am very ill for a long time and want to take the one where I would have the best change for improvement. Would appreciate your opinions. Thanks, H. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 29, 2001 Report Share Posted July 29, 2001 At 06:48 29/07/01, you wrote: >My question is and can't seem to find it in the web sites that I have looked >at is Transfer Factor #2 or TF C made from human blood? No - the only TF that I know is made from Human blood is the Cuban one that is listed under links on my website. By definition this cannot be a " specific " TF to all those bugs that TF#2 and TF C are supposed to be specific to, cos how would you know that all the people who contributed their blood had been exposed to HHV6 etc...? I think the Chisolm products are made from some kind of cell-line culture from chickens, but this might not be right... I must check at some stage. The reason Fudenberg liked using a close relative/co-habiter is because he could assume they had been exposed to whatever bugs were ailing you, so that they would have TF specific to all your bugs. I guess the jury is out as to how true that is in practice but it seems plausible. It seems he was heavily pressured and it is sad that he eventually gave it away. Cheers, n Quote Link to comment Share on other sites More sharing options...
Guest guest Posted July 31, 2001 Report Share Posted July 31, 2001 <<< The reason Fudenberg liked using a close relative/co-habiter is because he could assume they had been exposed to whatever bugs were ailing you, so that they would have TF specific to all your bugs. I guess the jury is out as to how true that is in practice but it seems plausible. It seems he was heavily pressured and it is sad that he eventually gave it away. >>> another problem with human tf is that it's extremely time consuming, and prohibitively expensive - unfortunately, couldn't be mass produced.... ~~~~~~~~~~~~~~~~~~~~~~~~~ " Would they have found nothing, unless nothing was what they wanted to find? " - Agent Dales, X-Files @}{~{<<~~~~~~~~~~~~~~~~~~~~ @}{~{<<~~~~~~~~~~~~~~~~~~~~ debbie s. - dlsherman@... Quote Link to comment Share on other sites More sharing options...
Guest guest Posted August 30, 2001 Report Share Posted August 30, 2001 Moonbeam, (I know already what a profilic writer is, so I don't need your answer any longer) Good information. Thanks for this. But I got all this also from Felix . And that makes it for me reasonable reliable, though I stay suspicious as always (in a good way I hope) . Felix and his company give also the studies where transfer factor plus didn't work. But what I see and read is that transfer factor plus doesn't work on itself but as an adjuvant with chemo, surgery and radiation it makes a difference. Often a significant difference. Like almost all vitamins etc. do. And remarkable, in the informationbook of transfer factor plus also beta glucan, vitamin C, echinacea, berberine-containing herbs etc. are mentioned to take together with transfer factor plus. Important, but I don't know if this is true: I got information that the company who sells transfer factor plus has got a patent on this product because they isolated a certain substance and add then vitamins etc. (How do you say that in english, boosting immunesystem products? ) which are not to be patented. Then in studies when they have good results they give the credits to the transfer factor, but they don't say anything about the vitamin C for example because that aren't patented substances. But I've heard this and cann't prove that with hard conclusions and written statements. But it is remarkable because some Chinese herbs like Zhuling, Kanglaite etc. show the same process when they are used as an adjuvant with chemo , surgery and radiation. Another thing what I see and read in all the information about transfer factor plus is that transfer factor plus works better in cancers like leukemia, non-Hogdkin etc. Blood and boonmarrow related kind of cancers. Though the study with post surgery therapy also shows a good effect. I think this is interesting and confirms in my opinion that every kind of cancer needs a basic treatment of a good diet with supplements, but needs also a specialised advise from a specialised orthomolecular doctor which supplements are the best for that kind of cancer. Breastcancer needs a different approach than leukemia for example. And confirms also in my opinion the way of thinking that a good diet with certain nutritional supplements in addition to regular treatments (not always though) will give us more chance to survive our cancer. I think it isn't smart to skip all regular treatment, though for certain cancers chemo doesn't work at all (according to Ralph Moss, but that is mentioned before in this group) But ofcourse one should always consult a specialised doctor. Gr. Kees Braam webmaster www.kanker-actueel.nl Caroleans mother/transfer factor plus? > > Did your mother tried Transfer factor plus?. It seems if I may believe the > > testimonials (I got them from the company who sells this product so > > there is some suspicious reading needed) > > Hi, > there is no need to be suspicious or to rely on testimonials. Instead always > search the medline for clinically proven results. I do that everyday. > Transfer Factor is not the best immune stimulant, beta glucan is the best and most > comprehensive immune stimulant. rather Transfer Factor (T.F.) is a natural killer > activator like MGN-3, but unlike MGN-3 it teaches natural killer cells exactly what > antigens to look for. > Unlike beta glucan it does not activate macrophages which are the master controllers of > the immune system through the cytokine regulated immune cascade. > Nevertheless transfer factor is a part of Protocol 1. > > If one cant understand abstracts from medical journals, try just reading the last > sentence, as this usually contains the summary of findings. > > moonbeam > > 1: Cancer 1996 Nov 1;78(9):1892-1898 > > Postoperative immunostimulation after complete resection improves survival of > patients with stage I nonsmall cell lung carcinoma. > > Fujisawa T, Yamaguchi Y. > > Department of Surgery, Chiba University School of Medicine, Japan. > > BACKGROUND: approximately 40% of primary lung carcinoma patients who die within > 1 month after a complete resection have residual tumor in regional or distant > organs, emphasizing the importance of postoperative adjuvant therapy. In this > study, the effectiveness of transfer factor (TF) and nocardia rubra-cell wall > skeleton (N-CWS) as adjuvant therapy for patients with primary, completely > resected nonsmall cell carcinoma of the lung was evaluated in a randomized > controlled trial METHODS: A total of 82 patients with Stage I disease who had a > complete resection were allocated randomly into 2 groups: TF + N-CWS (n = 41) or > control (surgery only) (n = 41). RESULTS: The distributions of age, sex, > histology, differentiation, T classification, tumor size, visceral pleural > invasion, and the site of origin, were similar in the two groups. The 5- and > 10-year disease specific survival rates in the TF + N-CWS group were 85% and > 85%, respectively, and those in the control group were 72% and 64%, > respectively. There was a statistically significant difference between the two > groups (P = 0.041). When the survival was analyzed according to clinical > characteristics, significant differences were observed in patients with no > visceral pleural invasion or with T1 disease. The frequency of distant > metastasis was significantly less in the TF + N-CWS group than in the control > group. CONCLUSIONS: These results indicate that TF + N-CWS is beneficial as > adjuvant therapy after surgical treatment of Stage I nonsmall cell carcinoma of > the lung. > > Publication Types: > Clinical trial > Randomized controlled trial > > PMID: 8909308 [PubMed - indexed for MEDLINE] > > > > > 2: Zhonghua Zhong Liu Za Zhi 1993 Nov;15(6):435-437 > > [Effect of hepatocellular carcinoma-specific transfer factor (HCC-S-TF) on IL-2 > activity and IL-2R expression]. > > [Article in Chinese] > > Pen GY. > > Third Military Medical University, Chongqing. > > HCC specific transfer factor (S-TF) was extracted from lymphoid tissues of goats > immunized with HCC cell suspension. The effect of the S-TF on IL-2 activity and > IL-2R expression was observed in vitro. The results showed that IL-2 activity > and IL-2R expression in HCC patients but not in normal subjects could be > increased by the S-TF. The IL-2 activities and IL-2R expressions in both normal > subjects and patients with HCC could not be increased by normal transfer factor > (N-TF). This may be one of the anti-tumor mechanisms of S-TF. It suggests that > S-TF may be better than N-TF in immunotherapy of human tumors. > > PMID: 8200281 [PubMed - indexed for MEDLINE] > > > > > 3: Ann Thorac Surg 1992 Mar;53(3):391-396 > > Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term > follow-up. > > Whyte RI, Schork MA, Sloan H, Orringer MB, Kirsh MM. > > Section of Thoracic Surgery, University of Michigan, Ann Arbor. > > Transfer factor, a dialyzable lymphocyte extract that may act as an immune > stimulator by transferring antigen-specific immunity between genetically > dissimilar individuals, was administered in a prospective, randomized study to > patients with non-small cell bronchogenic carcinoma. Between 1976 and 1982, 63 > patients who underwent pulmonary resection, mediastinal lymph node dissection, > and, when indicated by the presence of mediastinal lymph node involvement, > mediastinal irradiation were randomized into two groups. Group 1 (n = 28) > received 1 mL of pooled transfer factor at 3-month intervals after operation; > group 2 (n = 35 ) served as controls and received saline solution. There were no > statistically significant differences between the two groups with respect to > age, sex, tumor histology, stage of disease, or extent of resection. One patient > was lost to follow-up at 96 months; follow-up was complete in all others through > July 1990. In patients receiving transfer factor, the 2-, 5-, and 10-year > survival rates were 82%, 64%, and 43% respectively, whereas in controls they > were 63%, 43%, and 23%. Survival in patients receiving transfer factor was > consistently better than in those receiving placebo. Furthermore, survival in > patients receiving transfer factor was greater at all stages of disease for both > adenocarcinoma and squamous cell carcinoma. Although these long-term results > were not statistically significant using survival analysis with covariates (p = > 0.08), they confirm our previously reported short-term findings suggesting that > administration of transfer factor, either through nonspecific immune > stimulation, enhancement of cell-mediated immunity, or an as yet undefined > mechanism, can improve survival in patients with bronchogenic carcinoma. > > Publication Types: > Clinical trial > Randomized controlled trial > > PMID: 1540053 [PubMed - indexed for MEDLINE] > > > > > 4: Semin Surg Oncol 1991 Jul;7(4):221-229 > > Immunotherapy of renal cell cancer. > > Crusinberry R, RD. > > Department of Urology, University of Iowa, Iowa City 52242. > > Immunotherapy of metastatic renal adenocarcinoma (RCC) is currently an > alternative to cytotoxic chemotherapy. Bacillus Calmette-Guerin has been > associated with a 22% response rate in small series, but no large-scale clinical > trials have been completed. Transfer factor, in combination with other > immunotherapeutic and chemotherapeutic compounds, has a reported 13% incidence > of response. Tumor vaccines have caused clinical response in only 5% of patients > while monoclonal antibodies have produced partial remission in one of nine > patients. Immune RNA has been associated with a 14% overall incidence of > response. Tumor necrosis factor has not as yet been studied in any large-scale > clinical investigations but preliminary studies are not promising. > Leukocyte-derived and recombinant interferons alone have produced responses in > 10-20% of patients with tolerable toxicity. Combinations of interferons or with > cytotoxic chemotherapy have produced slightly improved responses with short > duration and substantial toxicity. Adoptive immunotherapy using Interleukin-2 > alone, or with IL-2 plus lymphocyte-activated killer cells, or tumor > infiltrating lymphocytes or interferons have produced clinical responses in > 10-30% of patients treated. Combinations of specific forms of immune therapy may > hold promise for better rates of clinical response in the future. > > Publication Types: > Review > Review, tutorial > > PMID: 1925254 [PubMed - indexed for MEDLINE] > > > > > 5: Ann Allergy 1989 Mar;62(3):170-176 > > Biological response modifiers. Interferons, interleukins, and transfer factor. > > Kirkpatrick CH. > > Department of Medicine, National Jewish Center for Immunology and Respiratory > Medicine, Denver, Colorado. > > Natural consequences of knowledge of the mechanisms that regulate immune > responses are the attempts to modify the immune system in order to increase > resistance to infectious diseases and to enhance activity against tumor cells. > This review describes the roles of interferons and interleukins in immune > responses and reviews the experience with transfer factor in treatment of > certain diseases. > > Publication Types: > Review > Review, tutorial > > PMID: 2466425 [PubMed - indexed for MEDLINE] > > > > > 6: Cancer 1988 Apr 15;61(8):1543-1549 > > A randomized, double-blind, placebo-controlled trial of transfer factor as > adjuvant therapy for malignant melanoma. > > LL, Spitler LE, RE, Minor DR. > > M. Aggelar Memorial Laboratory, Children's Hospital of San Francisco, > California. > > One hundred and sixty-eight evaluable patients participated in a randomized, > double-blind study of transfer factor (TF) versus placebo as surgical adjuvant > therapy of Stage I and Stage II malignant melanoma. Eighty-five patients > received TF prepared from the leukocytes of healthy volunteer donors; > eighty-three participants received placebo. Therapy was initiated within 90 days > of resection of all evident tumor and continued until 2 years of disease-free > survival or the occurrence of unresectable dissemination of melanoma. Known > prognostic variables were similarly distributed in the treatment and control > groups, documenting the randomization efficacy. Three endpoints were analyzed: > disease-free interval, time to Stage III metastasis, and survival. After a > median follow-up period of 24.75 months, there was a trend in favor of the > placebo group with regard to all three endpoints and this was significant (P > less than or equal to 0.05) for time to Stage III metastasis. These findings > indicate that TF is not effective as surgical adjuvant therapy of malignant > melanoma. > > Publication Types: > Clinical trial > Randomized controlled trial > > PMID: 3280114 [PubMed - indexed for MEDLINE] > > > > > 7: J Exp Pathol 1987;3(4):549-564 > > Clinical trials of transfer factor in malignancy. > > Spitler LE, L. > > M. Aggelar Memorial Laboratory, Children's Hospital of San Francisco, > California 94118. > > Results of clinical trials of transfer factor therapy in various malignancies > have been variable. In non randomized trials, about 300 patients have been > evaluated, and clinical benefit has been reported in about 1/3 of the evaluable > patients. Results of randomized studies are similarly varied. In some randomized > trials, clinical benefits of increased disease free survival and prolonged > survival have been claimed. In other studies, transfer factor has been reported > to be of no clinical benefit. In a few studies, results suggest patients > receiving transfer factor do not do as well as those receiving placebo, although > these are only trends, and do not reach the level of statistical significance. > There are a number of variables in the design of transfer factor trials, and > review of the studies performed to date does not permit a determination of > which, if any, of these variables is related to the therapeutic outcome. A > variety of tumor types have been evaluated, and it is not clear which, if any, > tumors respond to transfer factor. Similarly, the state of disease and prior and > concomitant therapy vary widely in these trials and the impact of these > variables is unclear. The source and dose of transfer factor also varies. In > some studies, attempts have been made to select donors who might have cellular > immune reactivity to the tumor being treated, whereas in other studies normal > donors have been used. The rationale for the use of normal donors in that the > clinical benefit of transfer factor may be related to the non specific > immunopotentiating effects of this agent rather than the specific transfer of > cellular immunity. Finally, the methods of preparation of transfer factor vary > and the products used in various studies cannot be compared by standard biologic > or biochemical tests currently available. This review of the literature > regarding the clinical effort of transfer factor in malignancy leads to the > conclusion that transfer factor might not be an effective therapy of cancer. If > it does have efficacy in certain malignancies, it is unlikely that it will alone > have dramatic effects in substantial numbers of patients. Perhaps transfer > factor may have a role in tumor therapy as an adjuvant to other forms of therapy > and as surgery, irradiation, or chemotherapy. In order for the proper evaluation > of transfer factor in reproducible comparative studies, it will be necessary to > have a standarized reproducible product which can be assessed by appropriate > quality control procedures.(ABSTRACT TRUNCATED AT 250 WORDS) > > Publication Types: > Clinical trial > Review > Review, tutorial > > PMID: 3331650 [PubMed - indexed for MEDLINE] > > > > > 8: Nippon Geka Gakkai Zasshi 1985 Sep;86(9):1055-1058 > > [The results of immunotherapy as an adjunct to the surgical treatment of primary > lung cancers]. > > [Article in Japanese] > > Fujisawa T. > > A total of 263 primary non-small cell lung cancer patients resected in our > Institute from March, 1978 to October, 1984 were utilized in order to evaluate > the efficacy of transfer factor (TF) immunotherapy as an adjunct to surgical > treatment and TF was significantly effective to cases with stage I diseases, but > not to stages II, III and IV diseases, indicating that TF could only suppressed > micrometastasis existing at the time of surgery. In order to improve the further > results of immunotherapy as an adjunct to surgical treatment, we analyzed > cytotoxic activity against autologous lung cancer and K562 leukemia cells in > tumor bearing hosts. Furthermore, we studied the effect of interleukin 2 (IL2) > activated lymphocyte dialysate on cytotoxic activity against lung cancer cells. > When 3 different sources of lymphocytes including peripheral blood lymphocytes > (PBL) regional lymphnode cells (LNC) and tumor infiltrating lymphocytes (TIL) > were incubated with IL2 for 8 days at 37 degrees C in 5% CO2 atmosphere, > relatively high cytotoxic activity was demonstrated with 2 major different > patterns in PBL, LNC and TIL including one systemic predominant and the other > local predominant patterns, suggesting that IL2 might be a local or systemic > possible immunotherapeutic reagent. Finally, we stimulated lymphocytes from > household contact family members with IL2 and MMC treated lung cancer cells. > These in vitro modulated T-lymphocytes demonstrated considerable cytotoxic > activity against the target cells which were used as in vitro sensitization. The > dialysate of these in vitro stimulated cells showed specific activity on > cytotoxicity against lung cancer cells and might be a possible reagent in stead > of TF for clinical trial. > > PMID: 3878937 [PubMed - indexed for MEDLINE] > > > > > 9: Am J Reprod Immunol Microbiol 1985 Jul;8(3):80-83 > > Effect of transfer factor on tumor-associated immunity and tumor growth of the > Dunning R-3327G rat prostate adenocarcinoma. > > Shaw MW, Ablin RJ, Guinan PD, Bhatti RA. > > Of importance in the design and application of improved or new modalities of > treatment are their evaluation on relevant animal models. In the case of > prostate cancer (PCa) the Dunning R-3327 rat prostate adenocarcinoma (PCa), and > its variant sublines, is one such experimental tumor model of its human > counterpart. In a preliminary study, the effect of transfer factor (TF), one > form of passive immunotherapy, on tumor-associated immunity (TAI) and tumour > growth and histology of the G subline (a poorly differentiated, fast-growing, > androgen sensitive, and poorly metastatic tumour of the Dunning R-3327 rat PCa) > has been evaluated. TF prepared from the leukocytes of tumor-bearing animals and > nontumor-bearing animals referred to as sensitized (STF) and unsensitized (UTF), > respectively, had no significant effect on TAI or tumor size. The only > noticeable effect of TF in this study was the presence of variable and moderate > lymphocytic infiltrates, necrosis, and degenerative-type cells in tumors of > animal recipients of STF. The failure to observe significant differences in TAI > among tumor bearing and nontumor bearing animals raises doubt in part, of the > immunogenicity of the G subline tumor and its appropriateness, at least for > subsequent immunological studies. Further factors considered in this regard, are > questions of tumor load, including the possible need for the use of adjuvant, > and the parameters and sensitivity of immune responsiveness selected for > evaluation and immunocompetency. Subsequent evaluation of the effect of TF on > other more immunogenic variant sublines of the Dunning R-3327 rat tumor may yet > provide further and more useful information. > > PMID: 4025670 [PubMed - indexed for MEDLINE] > > > > > and the study results the best > > product fo= r stimulating the immunesystem beside other products ofcourse > > like mentione= d before in this mailgroup. > > > > > I got this from Felix the person who is the main seller of these > > pro= ducts, so his purpose is to sell a lot of this stuff, but anyhow it > > is quit= e amazing what the site tells about the experiences with TRansfer > > factor pl= us. And the studies I got send home are quite good. Also an > > independient ra= ndomised study. But maybe you can ask Felix to send you > > the same material= > > he sended me.. > > > > First, you may want to read the testimonials of successful product users, > > a= s they can explain their triumphs with the product far better than I > > ever c= ould. They're available here: > > http://www.explode-web-traffic.com/map/testim= onials. This takes a while > > to load, but well worth the wait. This page is t= hat extensive and it's a > > small representation of the actual testimonial vol= ume. Cancer patients > > have testified here. > > > > Gr. Kees Braam > > webmaster www.kanker-actueel.nl > > > > Get HUGE info at http://www.cures for cancer.ws, and post your own links there. Unsubscribe by sending email to cures for cancer-unsubscribeegroups or by visiting http://www.bobhurt.com/subunsub.mv > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 9, 2002 Report Share Posted March 9, 2002 In a message dated 3/9/02 5:57:59 PM Central Standard Time, careysullins@... writes: > > I also do many other supplements and things but I would suggest giving > Which on are you suggesting we should take? What company? Carole Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 23, 2002 Report Share Posted March 23, 2002 Yes, this could easily be a herxeimer reaction. It means you are killing something. Thanks, Doris ----- Original Message ----- From: " stevendupre " <stevendupre@...> > Hello, > I have had sore neck glands and a slight fever on my very first day > taking just one transfer factor capsule. Is this normal? > Steve Du Pre Quote Link to comment Share on other sites More sharing options...
Guest guest Posted March 29, 2002 Report Share Posted March 29, 2002 I assume you are talking about the supplement, " transfer factor. " My dr. has recommended a different brand which calls its product " Immune support factors " by chisolm labs (chisolmbio.com). Its supposedly less costly (under $50 I think). I have had two blood tests since being on it, and due for a third in a couple of weeks. After the first test, my NKC increased a little, but my dr. said that the two main products she recommends both provide charts that show only minimal increases during the first month. However, after the first month the increases generally are more noticeable. Unfortunately, my second test showed a DECLINE in NKC, but I was also in the middle of a lupus flare and both my ANA and cardio crp were elevated. So, I guess the true test as to whether I will stay on this product, or switch brands, will be based on my third blood test. Annette Annette Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 8, 2002 Report Share Posted June 8, 2002 <<< Has anyone on this list had or know of anyone who has had real " human " transfer factor taken from a close relative that had contact with them at onset? >>> hi cathy - yes - i know a mother who donated to a daughter. this was years ago - in the '80s. it helped her a while, then, like so many other things, stopped. the mother was later dx'd with cfs, though milder than the daughter. it was also prohibitively expensive and time consuming.... ~~~~~~~~~~~~~~~~~~~~~~~~~ " Would they have found nothing, unless nothing was what they wanted to find? " - Agent Dales, X-Files @}{~{<<~~~~~~~~~~~~~~~~~~~~ @}{~{<<~~~~~~~~~~~~~~~~~~~~ debbie s. - dlsherman@... Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 23, 2002 Report Share Posted September 23, 2002 www.antibioticfailure.com/je/ transfer factor > below I will post what I found to be a particularly interesting study > I found. Not a silver bullet, but perhaps an aid in the arsenal. As > I have been reading about TF's this evening, I have noticed that > perhaps not all are created equal, and this study points to specific > TF vs. non-specific TF. > > here is a websight to get you started if your interested: > http://www.transferfactor.ws/ > > Just FYI > Chris > > > > > Transfer factor in chronic mucocutaneous candidiasis > > Massimo Masi(1), Caterina De Vinci(2), Olavio o Baricordi(3). > > (1)Allergology and Clinical Immunology Center, Department of > Pediatrics, University of Bologna; (2)Experimental Urology Unit, > Division of Urology - S.Orsola-Malpighi Hospital, Bologna, Italy. (3) > Department of Genetics, University of Ferrara, Italy > > Fifteen patients suffering from chronic mucocutaneous candidiasis > were treated with an in vitro produced TF specific for Candida > albicans antigens and/or with TF extracted from pooled buffy coats of > blood donors. CMI of the patients was assessed using the LMT and the > LST in presence of candidine. The aim of the study was the clinical > evaluation of TF treatment and the incidence of positive tests > before, during, and after therapy. Immunological data were matched > using the Chi square test. 87 LMT were performed for each antigen > dose and, at the dilution of 1/50, 58.9% (33/56) tests were positive > during non-treatment or non-specific TF treatment. On the contrary > 83.9% (26/31) were positive during specific TF treatment (P<0.05). In > the LST, a significant decrease of thymidine uptake in the control > cultures in presence of autologous or AB serum was observed when > patients were matched according to non-treatment, and both non > specific (P<0.05) and specific TF treatment (P<0.01). Only during > specific TF treatment was a significant increase of reactivity > against the Candida antigen at the highest concentration noticed when > compared with the period of non specific treatment (P<0.01). Clinical > observations were encouraging: all but one patient experienced > significant improvement during treatment with specific TF. These data > confirm that orally administered specific TF, extracted from induced > lymphoblastoid cell-lines, increases the incidence of reactivity > against Candida antigens in the LMT. LST reactivity appeared not > significantly increased with respect to the periods of non treatment, > but was significantly increased when it was compared to the non- > specific TF treatment periods. At the same time, a clinical > improvement was noticed. > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 24, 2002 Report Share Posted September 24, 2002 Thank-you for your post! My son has Chronic Mucocutaneous Candidiasis, which is a rare form of candidiasis sadly enough. I too have been doing alot of studying into TF, glad you shared this site! Angie Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 24, 2002 Report Share Posted September 24, 2002 In a message dated 9/23/02 7:35:58 PM Pacific Daylight Time, noo.dle@... writes: will a stool test or comprehensive stool analysis pick up this rare form of candida > (mucocutaneous candidiasis)? thank you > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 24, 2002 Report Share Posted September 24, 2002 I honestly do not know the answer to this question.......I would think that the main question is...would the attending doctor recognize/know what chronic mucocutaneous candidiasis is and know how to treat it????? I have found this to be a problem in the past. My son (actually my step-son) had it from the time he was an infant, inherited it from his birth mother. He had plenty of signs and symptoms but was not diagnosed until he was two and a half years old. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 25, 2002 Report Share Posted September 25, 2002 Here is a transfer factor that is supposedly made specifically for candida: ImmunFactor( 1 (Keep refrigerated): HIV, Pneumocystic carinii, Human tuberculosis, Bovine tuberculosis, Epstein-Barr Virus (EBV), Herpes 1, Herpes 2, Human herpes virus 6 ( HHV6), Candida albicans, Cryptosporosis, and Mycobacterium avian Chris ps. I just ordered a different product from this company for a different reason, and I'll post in time as to the outcome. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 25, 2002 Report Share Posted September 25, 2002 do you have a link for this?? Re: transfer factor > > Here is a transfer factor that is supposedly made specifically for > candida: > > ImmunFactor( 1 (Keep refrigerated): > > HIV, Pneumocystic carinii, Human tuberculosis, Bovine tuberculosis, > Epstein-Barr Virus (EBV), Herpes 1, Herpes 2, Human herpes virus 6 ( > HHV6), Candida albicans, Cryptosporosis, and Mycobacterium avian > > > > Chris > ps. I just ordered a different product from this company for a > different reason, and I'll post in time as to the outcome. > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 25, 2002 Report Share Posted September 25, 2002 Here is the company that makes it: http://www.chisolmbio.com/ Its not inexpensive though...about $135.- month I think. I spoke to the owner who was happy to answer my questions. Alot of money, but I figure if it works....hey. This site talks about different makes of transfer factor and provides some studies: http://www.transferfactor.ws/ Good luck, Chris > do you have a link for this?? > Re: transfer factor > > > > > > Here is a transfer factor that is supposedly made specifically for > > candida: > > > > ImmunFactor( 1 (Keep refrigerated): > > > > HIV, Pneumocystic carinii, Human tuberculosis, Bovine tuberculosis, > > Epstein-Barr Virus (EBV), Herpes 1, Herpes 2, Human herpes virus 6 ( > > HHV6), Candida albicans, Cryptosporosis, and Mycobacterium avian > > > > > > > > Chris > > ps. I just ordered a different product from this company for a > > different reason, and I'll post in time as to the outcome. > > > > > > > > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.